Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib

por Guo, Weihong, Liang, Jianping, Zhang, Dandan, Huang, Xikun, Lv, Yanhua
Publicado 2022

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma

por Zhang, Dandan, Liang, Jianping, Lv, Yanhua, Huang, Xikun, Guo, Weihong
Publicado 2022